Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure characterized by impaired cardiac filling. In a recent study, his group and ...

A new experimental therapy helps restore the heart’s flexibility in models of stiffened heart failure. Michael Gotthardt and his colleagues at the Max Delbrück Center are working with U.S. researchers ...

An immune cell type called macrophages, found throughout the body's tissues, are often referred to as the body's clean-up ...

A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a ...

Uncertainty surrounding how truncated titin proteins (TTNtvs) cause dilated cardiomyopathy (DCM) and peripartum cardiomyopathy (PPCM) led to investigations that could better inform therapies for these ...

Preclinical studies show that engineered heart muscle (EHM) can remuscularize damaged heart tissue, but most evidence comes from small-animal studies, which have limited ability to predict outcomes in ...

A naturally occurring gene called Cyclin A2 (CCNA2), which turns off after birth in humans, can actually make new, functioning heart cells and help the heart repair itself from injury, including a ...

Heart failure (HF) is one of the leading causes of death and disability worldwide, affecting millions of people and placing ...

When someone has a heart attack or heart failure, heart muscle cells are lost and the heart cannot replace ... keeping their structure and function and demonstrating normal protein and calcium ...

Heart failure (HF) has long been blamed on weakened heart muscle cells, but new research shows that support cells called fibroblasts may be a key factor. Researchers found that fibroblasts send ...